Latest News for: fshd

Edit

Urgent wait for treatments: The race against time in the fight against FSHD, a genetic ...

Pittsburgh Tribune Review 12 Oct 2024
Food and Drug Administration has not yet approved any treatments to stop the progression or increase muscle mass in people with facioscapulohumeral muscular dystrophy (FSHD), a genetic disorder that weakens skeletal muscles.
Edit

Fast Skeletal Muscle Troponin Activator CK-4015089 Improves Muscle Function in a FSHD Mouse Model with Muscle Weakness (Cytokinetics Incorporated)

Public Technologies 07 Oct 2024
FSHD Mouse Model with Muscle Weakness ... CK-4015089 reduced repetitive nerve stimulation-induced muscle fatigue in FSHD mice ... • The ACTA1-MCM;FLExD FSHD mouse ... Mild FSHD + Vehicle (PO, n=13). Mild FSHD + CK-4015089 (28 mg/kg, PO, n=15) ... Mild FSHD.
Edit

World FSHD Day resolution introduced on Capitol Hill

Pittsburgh Tribune Review 26 Jun 2024
Christman, a retired attorney and board member of Trib Total Media, was diagnosed with facioscapulohumeral muscular dystrophy, or FSHD, in 1977 at age 16 ... While FSHD is primarily hereditary, 30 percent of people have no family history of it.
Edit

Reps. Kelly, Dingell Introduce Resolution Honoring World FSHD Day (Mike Kelly)

Public Technologies 24 Jun 2024
Representatives Mike Kelly (R-PA) and Debbie Dingell (D-MI) introduced a bipartisan resolution honoring June 20, 2024, as World Facioscapulohumeral Muscular Dystrophy (FSHD) Day. FSHD is a genetic ...
Edit

Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on ...

Moscow-Pullman Daily News 21 Jun 2024
FSHD Society to host Avidity webinar on positive initial data from the Phase 1/2 FORTITUDE™ trial for people living with FSHD today at 1.00 p.m. ET ... .
Edit

Dingell, Kelly Introduce Resolution Honoring World FSHD Day (Debbie Dingell)

Public Technologies 20 Jun 2024
) Representatives Debbie Dingell (D-MI) and Mike Kelly (R-PA) this week introduced a bipartisan resolution honoring June 20, 2024, as World Facioscapulohumeral Muscular Dystrophy (FSHD) Day. FSHD is a ...
Edit

Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day

PR Newswire 20 Jun 2024
A recording of this webinar will be available on FSHD Society's FSHD University at a later date ... FSHD through World FSHD Day and to recognize patients and families worldwide who are affected by FSHD.
Edit

Springbok Analytics Announces Phase 1 Clinical Trial Evaluating Clenbuterol as FSHD Treatment

My Horry News 13 Jun 2024
This dose escalation study for safety and tolerability of clenbuterol incorporates Springbok's precision muscle MRI analysis and molecular outcome measures ....
Edit

Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress

Nasdaq Globe Newswire 12 Jun 2024
... of patients enrolled in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD).
Edit

Epic Bio to Present IND-Enabling Data Package for EPI-321 at FSHD International Research Congress

Nasdaq Globe Newswire 07 Jun 2024
Epic Bio to present highlights of IND-enabling data package for lead candidate EPI-321 in FSHD at FSHD International Research Congress ... .
Edit

Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress

PR Newswire 29 May 2024
4.50 pm MDT Interim Results from FORTITUDE™, a Randomized Phase 1/2 Trial Evaluating AOC 1020 in Adults with FSHD ... ET to discuss the preliminary data from the FORTITUDE™ trial of AOC 1020 in people living with FSHD.
Edit

Epic Bio Presents New Data Highlighting Potential of EPI-321 for FSHD and Epigenetic Editing Platform ...

Nasdaq Globe Newswire 23 Apr 2024
- Across robust slate of presentations, company highlights compelling new data and strong differentiation -. - Across robust slate of presentations, company highlights compelling new data and strong differentiation - ... .
Edit

Epic Bio Presents Compelling Preclinical Data Supporting Clinical Initiation of EPI-321 for FSHD

Nasdaq Globe Newswire 16 Jun 2023
- NHP studies demonstrate EPI-321’s favorable safety and pharmacokinetic profile - ... .

Most Viewed

×